Visit https://www.peervoice.com/RJT860 to view the entire programme with slides. After completing “Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?”, participants will be able to: Explain the unmet medical needs in diffuse large B-cell lymphoma (DLBCL); Assess the latest clinical data for novel and emerging antibody strategies for the treatment of relapsed/refractory DLBCL; Translate available clinical data for immunotherapeutic strategies into practical guidance for the clinic in order to maximise patient outcomes.

Visit https://www.peervoice.com/GFQ860 to view the entire programme with slides. After completing “Going the Distance in HIV: Simplifying ART at Every Stage”, participants will be able to: Explain the rationale for assessing and addressing the need for simplification of ART; Evaluate clinical implications of recent data on simplified ART in a variety of patient scenarios; Develop simplified ART based on individual patient- and disease-related factors.

Visit https://www.peervoice.com/QZT860 to view the entire programme with slides. After completing “Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?”, participants will be able to: Discuss the rationale for checkpoint inhibitors in the management of advanced or recurrent endometrial cancer; Evaluate recent data for current and emerging checkpoint inhibitors for the management of advanced or recurrent endometrial cancer; Identify common and serious adverse events associated with checkpoint inhibitors and their management in advanced or recurrent endometrial cancer.

Visit https://www.peervoice.com/WKG860 to view the entire programme with slides. After completing “Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)”, participants will be able to: Outline the characteristics of the high-risk versus the low-risk patient with CLL; Discuss therapy options to maximize treatment outcomes in the low-risk and high-risk patient with CLL.

Visit https://www.peervoice.com/EFT860 to view the entire programme with slides. After completing “Evaluating the Evidence for Managing CKD: Highlights From World Congress of Nephrology 2021”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.

Visit https://www.peervoice.com/FMS860 to view the entire programme with slides. After completing “Easy to Treat vs Easy to Manage Patients With HCV: What’s the Difference?”, participants will be able to: Explain the difference between patients with hepatitis C virus (HCV) infection that is easy to manage versus HCV infection that is easy to treat; Describe techniques to identify and treat patients with HCV, based on socioeconomic status and disease progression; Apply individualised strategies to manage different types of patients with HCV.

Visit https://www.peervoice.com/GSX860 to view the entire programme with slides. After completing “Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold”, participants will be able to: Recognise the challenges and limitations of current systemic treatment strategies for advanced basal cell carcinoma (aBCC) and how these impact patient outcomes; Describe the potential therapeutic targets related to aBCC and the emerging clinical data for these novel therapies as second-line treatment; Translate the evidence for emerging therapeutic strategies; Propose a treatment paradigm for patients with aBCC who have progressed on or are intolerant to prior Hedgehog pathway inhibitor therapy.

Visit https://www.peervoice.com/NVG860 to view the entire programme with slides. After completing “Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)”, participants will be able to: Identify effective therapeutic options in young patients with CLL, Discuss strategies to optimize outcomes in young patients with CLL.

Visit https://www.peervoice.com/XDM860 to view the entire programme with slides. After completing “Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs”, participants will be able to: Describe the rationale for GLP-1 receptor agonists (RAs) in the management of patients with type 2 diabetes (T2DM) as discussed in recent clinical guidelines; Evaluate the outcomes that will help achieve patient behaviour, such as weight loss and long-term benefits of controlling T2DM; Apply strategies to help patients overcome barriers to achieving long-term control of T2DM, including adherence to therapy and lifestyle changes.

Visit https://www.peervoice.com/VVA860 to view the entire programme with slides. After completing “Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC”, participants will be able to: Describe the unmet needs for patients with advanced NSCLC and how checkpoint inhibitors can address these challenges; Evaluate the most recent clinical evidence for current and emerging checkpoint inhibitors in the first-line management of advanced NSCLC with high PD-L1 expression; Discuss how emerging data may impact the treatment algorithm for patients with advanced NSCLC and high PD-L1 expression.